BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Isconova Enters into Adjuvant License Agreement with Crucell N.V. (CRXL)


6/9/2011 9:25:39 AM

June 09, 2011 -- Isconova has entered into a new license agreement with Crucell N.V.. The agreement grants Crucell the license to use Isconova’s adjuvant Matrix M™ in HIV and malaria vaccines. An existing agreement between Isconova and Crucell already granted Crucell the right to use Isconova’s Matrix M™ in influenza vaccines.

Lena Söderström, CEO of Isconova comments;

“Isconova’s Matrix M™ induces both antibody-mediated and cellular immune responses, making it particularly suitable for vaccines in a number of disease areas. We consider it a confirmation of the strengths of our product that Crucell has selected Matrix M™ for use in two additional vaccine areas.

In 2009, a clinical phase I trial with 60 subjects was completed by the PanFluVac consortium1, using Isconova’s Matrix M™ adjuvant in an avian influenza vaccine. The study showed that Isconova’s Matrix M™ adjuvant increased the number of antibody secreting cells and polyfunctional CD4+ Th1 cells. The vaccine met all set criteria and was well tolerated without any serious adverse events.

For more information, please contact:

Lena Söderström, CEO Isconova

Phone: +46 70-816 39 12, e-mail: lena.soderstrom@isconova.com

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has vast knowledge of vaccine systems and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2005. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.

Isconova was listed on NASDAQ OMX First North (ticker: ISCO) in November 2010. E. Öhman J:or AB is the Company’s Certified Adviser. www.isconova.com

About Matrix M™

Matrix M™ is an immune stimulating substance for use in vaccines, antibody production and immunological research. Adjuvants are substances added to vaccines for improved and lasting immune response in connection with vaccinations.

About HIV

HIV, short for human immunodeficiency syndrome, is a virus that affects the human immune system and causes AIDS. About 33 million people across the globe are estimated to be infected and the virus has, since its initial outbreak, cost 33 million human lives. About 7 000 people are estimated to be infected each day and more than 5 700 people die each day of HIV-related diseases.

About malaria

Malaria is a serious, and sometimes deadly, disease caused by an infection of single-celled parasites spread to humans via mosquito bites. The disease is widespread in the tropical and subtropical regions of the world, especially in Africa. Malaria afflicts 250 million people each year, and close to one million people die each year in complications related to the disease.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->